Antibiotic | Susceptible | Intermediate | Resistant |
Penicillin G (parenteral) | |||
Meningitis | ≤0.06 mcg/mL | – | ≥0.12 mcg/mL |
Nonmeningitis* | ≤2 mcg/mL | 4 mcg/mL | ≥8 mcg/mL |
Penicillin V (oral)* | ≤0.06 mcg/mL | 0.12 to 1 mcg/mL | ≥2 mcg/mL |
Amoxicillin (non-meningitis) | ≤2 mcg/mL | 4 mcg/mL | ≥8 mcg/mL |
Cefuroxime | |||
Parenteral | ≤0.5 mcg/mL | 1 mcg/mL | ≥2 mcg/mL |
Oral | ≤1 mcg/mL | 2 mcg/mL | ≥4 mcg/mL |
Cefotaxime, Ceftriaxone | |||
Meningitis | ≤0.5 mcg/mL | 1 mcg/mL | ≥2 mcg/mL |
Nonmeningitis | ≤1 mcg/mL | 2 mcg/mL | ≥4 mcg/mL |
Cefpodoxime | ≤0.5 mcg/mL | 1 mcg/mL | ≥2 mcg/mL |
Cefdinir | ≤0.5 mcg/mL | 1 mcg/mL | ≥2 mcg/mL |
Cefprozil | ≤2 mcg/mL | 4 mcg/mL | ≥8 mcg/mL |
Ceftaroline (nonmeningitis) | ≤0.5 mcg/mL | – | – |
Clindamycin | ≤0.25 mcg/mL | 0.5 mcg/mL | ≥1 mcg/mL |
Rifampin¶ | ≤1 mcg/mL | 2 mcg/mL | ≥4 mcg/mL |
Azithromycin | ≤0.5 mcg/mL | 1 mcg/mL | ≥2 mcg/mL |
Clarithromycin | ≤0.25 mcg/mL | 0.5 mcg/mL | ≥1 mcg/mL |
Gemifloxacin | ≤0.12 mcg/mL | 0.25 mcg/mL | ≥0.5 mcg/mL |
Levofloxacin | ≤2 mcg/mL | 4 mcg/mL | ≥8 mcg/mL |
Moxifloxacin | ≤1 mcg/mL | 2 mcg/mL | ≥4 mcg/mL |
* For nonmeningitis isolates, a penicillin MIC ≤0.6 mcg/mL can predict susceptibility to other beta-lactams as follows: ampicillin (oral or parenteral), ampicillin-sulbactam, amoxicillin, amoxicillin-clavulanate, cefaclor, cefdinir, cefditoren, cefepime, cefotaxime, cefpodoxime, cefprozil, ceftaroline, ceftizoxime, ceftriaxone, cefuroxime, doripenem, ertapenem, imipenem, loracarbef, and meropenem.
¶ Rifampin should not be used as monotherapy.Do you want to add Medilib to your home screen?